Law Office of Hong-min Jun · Chicago · Indianapolis
Biomedical Researcher
Neuroscience & Neurological Disease Research · Germany
Dr. R.K. holds a Ph.D. from Heidelberg University and a postdoctoral fellowship at Johns Hopkins Medical School. He specializes in the molecular mechanisms of neurodegeneration in Alzheimer's and Parkinson's disease. His research identified a novel tau protein aggregation pathway that is now a target for clinical trials at three major pharmaceutical companies, potentially affecting 6.7 million Americans with Alzheimer's.
Basic science NIW cases — particularly in neuroscience — can be difficult because the path from laboratory discovery to patient benefit is long. We needed to demonstrate that Dr. R.K.'s work had near-term national significance, not just long-term theoretical promise.
Dr. R.K.'s discovery of the MAPT-interacting protein complex has directly enabled three IND applications filed with the FDA for Alzheimer's therapeutics. His work is not theoretical — it is the mechanistic basis for ongoing Phase I clinical trials at Biogen, Eisai, and AstraZeneca.
Alzheimer's disease costs the U.S. $345 billion annually (Alzheimer's Association, 2023) and is the 7th leading cause of death. The National Plan to Address Alzheimer's Disease explicitly calls for accelerated mechanistic research — the exact type Dr. R.K. conducts. His NIH-funded research directly implements this national plan.
His ongoing NIH R01 grant ($1.8M) has federal reporting milestones that would be jeopardized by PERM delays. Additionally, his tau protein methodology is actively being replicated in 12 ANIA-funded labs — meaning a U.S. work interruption would disrupt a national research network dependent on his expertise.
Basic science cases win when you can draw a direct line from discovery to clinical trials. The IND application filings were the critical bridge — they proved that Dr. R.K.'s lab findings were not abstract but had already triggered regulatory-stage drug development. Pharmaceutical industry adoption of academic research is one of the strongest validators of national importance that USCIS encounters.
USCIS Approval Notice
Client identity redacted for confidentiality
Attorney Hong-min Jun can evaluate whether your background qualifies for NIW under the Dhanasar framework.
Request Free ConsultationAnalysis of AAO decision approving NIW for renewable energy researcher — publication impact and national interest contribution.
Why many NIW petitions fail at the National Importance prong in 2025, based on AAO decisions and practical case experience.
How the AAO evaluates recommendation letters in NIW petitions and what makes expert letters truly effective.
Every successful NIW case starts with a strategic assessment. Attorney Hong-min Jun will analyze your background against the Dhanasar framework and identify the strongest evidence for your petition.
Schedule Your Consultation